Array Biopharma Inc.

Invacare Corporation

Daniel John Watson

Christopher M Lindemann

Donald T Corson

James P Rizzi

Ellen Ruth Laird

Mark C Munson

Martha E Rodriguez

Robert D Groneberg

Charles Todd Eary

Darren Martin Harvey

Steven Wade Andrews

Damon Thomas Jurkiewicz

Laurence Edward Burgess

Shelley Allen

Robert Bekoscke

Daniel James Yee

Peter J Stengel

Weidong Liu

Traian Mohan

Stacey Spencer

Bruno P Hache

Derrick Juengst

C Todd Eary

Joshua Hamilton Greiner

Brian C Baer

Zackary D Crane

Laurence E Burges

Todd C Eary

Stacey Renee Spencer

Brian Baer

Zackary Crane

Polymorphs of N4-(4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)-3-methylphenyl)-N6-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine are provided herein. Processes for preparing the polymorphs and pharmaceutical composition comprising the polymorphs are also disclosed.

Polymorphs of ARRY-380, a selective HER2 inhibitor and pharmaceutical compositions containing them

Provided is Compound (I) or a pharmaceutically acceptable salt thereof, which is an inhibitor of TrkA kinase and is useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation and inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, pelvic pain syndrome, diseases related to an imbalance of the regulation of bone remodeling, and diseases resulting from Connective Tissue Growth Factor aberrant signaling. 

1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor

Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them

Provided herein are novel processes for preparing a compound of Formula (I) to the use of said compound as an intermediate in novel processes for the synthesis of indazole derivatives, and to indazole intermediates and derivatives prepared by the processes described herein. 

Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof

The compound of Formula (I) and pharmaceutically acceptable salts and prodrugs thereof are useful in the treatment and prevention of various disorders mediated by kinases. 

Kinase inhibitors and methods of use thereof

A compound of Formula II and salts thereof are useful in the preparation of a compound of Formula I and pharmaceutically acceptable salts and prodrugs thereof.

Growing community of inventors

Lafayette, CO, United States of America

Daniel John Watson